Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EBS 
Emergent Biosolutions Inc (EBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EBS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -42.01% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 540.22M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1442544 | Beta 1.57 | 52 Weeks Range 1.82 - 15.10 | Updated Date 03/31/2025 |
52 Weeks Range 1.82 - 15.10 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When Before Market | Estimate - | Actual -0.5775 |
Profitability
Profit Margin -18.55% | Operating Margin (TTM) 24.51% |
Management Effectiveness
Return on Assets (TTM) -4.22% | Return on Equity (TTM) -34.64% |
Valuation
Trailing PE - | Forward PE 14.56 | Enterprise Value 817410541 | Price to Sales(TTM) 0.25 |
Enterprise Value 817410541 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 0.81 | Enterprise Value to EBITDA 22.15 | Shares Outstanding 54184200 | Shares Floating 53116758 |
Shares Outstanding 54184200 | Shares Floating 53116758 | ||
Percent Insiders 2.15 | Percent Institutions 57.79 |
Analyst Ratings
Rating 3.67 | Target Price 12 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Emergent Biosolutions Inc
Company Overview
History and Background
Emergent BioSolutions Inc. was founded in 1998 as BioPort Corporation. It has evolved from focusing on biodefense to a broader approach in addressing public health threats, including infectious diseases and opioid overdoses.
Core Business Areas
- Products: Development, manufacturing, and sales of vaccines, therapeutics, and devices addressing public health threats.
- Services: Contract development and manufacturing (CDMO) services for pharmaceutical and biotechnology companies.
Leadership and Structure
The leadership team typically includes a CEO, CFO, and other executive officers. The company is structured with divisions focused on product development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- NARCAN Nasal Spray: An opioid overdose reversal medication. Market share fluctuates but is a leading product in its category. Competitors include generic naloxone products and other formulations like Kloxxado by Hikma. Estimated revenue for 2023 is $400 million. The competitor is Opiant Pharmaceuticals
- Anthrax Vaccines (BioThrax & AV7909 (NuThrax)): Vaccines for the prevention of anthrax. Key customers include the US government's Strategic National Stockpile. Competitors include other potential anthrax vaccine developers or suppliers. The competitor is Dynavax Technologies.
- Vaxchora: A vaccine against cholera. Revenue is lower than NARCAN or Anthrax vaccines but growing. Competitors include Dukoral and other preventative measures. Competitor is Valneva SE.
Market Dynamics
Industry Overview
The industry involves biodefense, vaccines, and therapeutics, driven by government contracts, public health needs, and pharmaceutical outsourcing.
Positioning
Emergent BioSolutions is a key player in biodefense and a growing player in public health. They have competitive advantages in government contracting and specialized manufacturing.
Total Addressable Market (TAM)
The TAM for biodefense and public health solutions is estimated to be multi-billion dollars annually, with Emergent positioned to capture a portion through government contracts and commercial products. This total addressable market is 20 Billion dollars.
Upturn SWOT Analysis
Strengths
- Strong relationships with government agencies
- Specialized manufacturing capabilities
- Established product portfolio in biodefense
- CDMO business provides diversified revenue
Weaknesses
- Dependence on government contracts
- Past manufacturing issues and regulatory scrutiny
- Debt load
- High Operating Cost
Opportunities
- Expanding CDMO services
- Developing new vaccines and therapeutics for emerging threats
- Acquiring complementary businesses
- Geographic expansion
Threats
- Changes in government funding and priorities
- Competition from larger pharmaceutical companies
- Regulatory changes
- Product liability risks
Competitors and Market Share
Key Competitors
- VTVT
- ABUS
- HZNP
Competitive Landscape
Emergent BioSolutions faces competition from both large pharmaceutical companies and smaller biotech firms. The company's competitive advantage lies in its specialized manufacturing capabilities and its relationships with government agencies.
Major Acquisitions
Adapt Pharma
- Year: 2018
- Acquisition Price (USD millions): 735
- Strategic Rationale: Acquisition of Adapt Pharma provided Emergent BioSolutions with NARCAN Nasal Spray, a leading opioid overdose reversal medication, diversifying their product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Analyze historical revenue and earnings growth rates.
Future Projections: Consult analyst estimates for revenue, earnings, and EPS growth for the next 1-3 years.
Recent Initiatives: Highlight recent acquisitions, product launches, or strategic partnerships.
Summary
Emergent BioSolutions is a company specializing in biodefense and public health threats. They have strong relationships with the government agencies. The stock has not performed well and faces competition from larger pharmaceutical companies and smaller biotech firms and high operating costs. They need to look out for government funding priorities and regulatory changes.
Similar Companies
ABUS
Arbutus Biopharma Corp
ABUS
Arbutus Biopharma Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
VTVT
vTv Therapeutics Inc
VTVT
vTv Therapeutics Inc
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports (e.g., from Yahoo Finance, Bloomberg)
- Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market data and analyst estimates are subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Emergent Biosolutions Inc
Exchange NYSE | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2006-11-15 | CEO, President & Director Mr. Joseph C. Papa Jr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 900 | |
Full time employees 900 | |||
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.